Merck Bcg Shortage

The BCG shortage is expected to continue for years. Clarification The story has been updated to clarify that a Merck facility to expand BCG production is expected to be completed between late

Merck just opened their new facility in NC on March 11, 2025. When the new facility is fully operational, we expect to triple our current manufacturing capacity of TICE BCG. I'm currently receiving 12 BCG doses due to the shortage. Although the 12 doses seems to be working, this will ensure there is enough to treat all of those who need

In recent years, Merck amp Co., as the biologic's sole manufacturer in the country, has struggled to keep pace with BCG demand. ImmunityBio, Serum Institute win FDA nod to combat BCG shortage Fierce

Tice BCG intravesical injection, Merck, 50 mg, single dose vial, 1 count, NDC 00052-0602-02 Reason for the Shortage Because of increased global demand, and as the only source of BCG Live Intravesical in the United States and many other countries, Merck anticipates supply constraints for Tice BCG in 2019.

Bacillus Calmette-Gurin BCG is a standard treatment option for non-muscle invasive bladder cancer. Merck amp Co., the only maker and supplier of BCG to the United States, has informed the Urology Care Foundation that they are now experiencing a global shortage of BCG due the growing use and need for this product around the world.

BCG Shortage The Practice Environment Seth P. Lerner, MD, FACS Professor of Urology Genentech, Merck, PfizerEMD Serono, Stimit, UroGen, Vaxiion, Verity Patent - TCGA classifier

An annual supply gap of more than 150,000 BCG vials could result. The report's appendix summarizes strategies to optimize BCG use. In late 2020, Merck announced plans to build a new manufacturing plant in North Carolina that could triple its BCG production, but a January 2023 announcement said the facility won't be completed for another 3 to 4

Messing EM. The BCG shortage. Bladder Cancer. 201733227-228. Merck. Merck Remains Committed to Producing TICE BCG for the Treatment of Certain Forms of Bladder Cancer. Merck. Published March 13, 2019. Accessed December 21, 2022. Merck. Merck to Construct New Facility in the United States to Expand Manufacturing Capacity for TICE BCG

Since 2012, when Merck became the sole manufacturer of TICE BCG BCG LIVE for intravesical use in many locations around the world, increasing global demand has outpaced our current maximum manufacturing capabilities. Committed to producing TICE BCG, in 2021 we announced our plans to construct a new manufacturing facility to significantly expand our production capacity for TICE BCG.

The BCG shortage in the United States has been primarily due to a reliance on a single manufacturer, Merck, which produces the TICE strain of BCG. This dependency became critical after Sanofi Pasteur ceased production of the Connaught strain in 2012, leaving Merck as the sole supplier for the U.S. and many other countries .